For newly diagnosed patients, the algorithm lays out treatment decisions based on starting A1C levels. Medication management is recommended for all patients in addition to lifestyle modification. Metformin, incretins, DPP4-inhibitors and alpha-glucosidase inhibitors are the drugs of choice, in the order listed, for initial therapy.
Sulfonylureas and thiazoladinediones are not first-line drugs.
A New York Times opinion piece by a doctor injects a note of caution. Were the guidelines unduly influenced by Big Pharma?